SMX Public Limited Company has announced the issuance of up to 27,534,449 Ordinary Shares according to a prospectus dated June 6, 2024. The prospectus outlines the resale of these shares by Selling Stockholders, which includes shares they currently hold, those they may acquire from converting a promissory note and a convertible security, as well as shares underlying warrants. The Selling Stockholders are permitted to sell their shares at market or negotiated prices, and these transactions may occur through broker-dealer arrangements or directly to dealers for resale. SMX will not receive any proceeds from the sales made by the Selling Stockholders. However, the company anticipates proceeds of approximately $1.86 million from the exercise of warrants by these stockholders. SMX, identified as an 'emerging growth...Show More

SMX Public Limited Company has announced the issuance of up to 27,534,449 Ordinary Shares according to a prospectus dated June 6, 2024. The prospectus outlines the resale of these shares by Selling Stockholders, which includes shares they currently hold, those they may acquire from converting a promissory note and a convertible security, as well as shares underlying warrants. The Selling Stockholders are permitted to sell their shares at market or negotiated prices, and these transactions may occur through broker-dealer arrangements or directly to dealers for resale. SMX will not receive any proceeds from the sales made by the Selling Stockholders. However, the company anticipates proceeds of approximately $1.86 million from the exercise of warrants by these stockholders. SMX, identified as an 'emerging growth company' and a 'foreign private issuer,' benefits from reduced public company reporting requirements. The company's Ordinary Shares are traded on The Nasdaq Capital Market under the ticker 'SMX,' with public warrants listed as 'SMXWW.' As of June 5, 2024, the closing price for SMX's Ordinary Shares was reported at $0.16. Potential investors are advised that investing in SMX carries risks, which are detailed starting on page 14 of the prospectus. Additionally, the company has experienced significant costs associated with compliance with U.S. reporting requirements, which could impact future financial results.